Innovent Bio 1H26 revenue jumps 55% to RMB 8.2B, beating estimates

Innovent Biologics (信达生物, 01801.HK) reported 1H26 product revenue of RMB 8.2 billion, up 55% year over year and far exceeding market consensus of RMB 6.9 billion.

"The latest product sales performance is particularly encouraging and is expected to lift the share price today," CLSA analysts wrote in a research note.

The beat comes as investors had worried that anti-corruption measures could weigh on the pharmaceutical sector's 1H26 results. The company's full-year 2025 product revenue reached RMB 11.9 billion, up 45% year over year, and management has set a target of RMB 20 billion in product revenue by 2027. For 2026, the company needs to deliver at least 30% year-over-year product revenue growth to stay on that trajectory, surpassing current analyst forecasts of around 20% annual growth.

Shares rose 3.979% on the announcement day. The earnings beat supports Innovent's dual-engine strategy spanning GLP-1 metabolic drugs and oncology, with new launches such as Mazdutide driving commercial momentum. The company reduced its net loss by 90.8% in the most recent reported period and targets net profit exceeding RMB 1.64 billion for full-year 2025, rising to RMB 6.68 billion in 2026. R&D expenses declined 28.6% in the prior period, though analysts project spending to recover to RMB 2.5-2.7 billion for FY25 as the company advances its pipeline.

The strong first-half performance shows Innovent's commercial execution is outpacing expectations even as the broader Chinese pharmaceutical sector navigates regulatory headwinds. The product revenue beat also provides a positive read-through for other HK-listed biopharma companies facing similar scrutiny from the anti-corruption campaign.

Product revenue is the primary indicator of Innovent's commercial success and market penetration across its diverse drug portfolio. The sustained high growth, particularly exceeding analyst expectations, supports the company's premium valuation and reinforces investor confidence in its long-term targets, including global expansion of its GLP-1 and oncology franchises. The company uses product revenue growth as the key metric for confirming its commercial strategy and pipeline execution.

Investors will watch the full-year 2025 results for updated 2026 guidance and whether the company can sustain the growth needed to hit its RMB 20 billion product revenue target by 2027. The next earnings report will also clarify whether R&D spending returns to growth as the company advances its pipeline candidates.

This article is for informational purposes only and does not constitute investment advice.